You can usually tell where a deal is going to get difficult.

Not at the beginning. That part usually moves pretty fast. The data looks solid, the positioning makes sense, and there’s enough alignment to justify pushing forward. On the surface, everything lines up.

The trouble shows up later.

It happens the moment the conversation shifts from what the asset is to how it actually has to be developed, manufactured, and approved across regions. That’s when the real shape of the opportunity starts to reveal itself. And it’s not always as clean as it first looked.

In 2026 this pattern has become impossible to ignore. Most deals aren’t dying because the science is weak. They slow down or quietly stall because the operational reality introduces a level of complexity nobody fully saw at the start.

Where the Narrative Shifts

Early conversations hold together as long as they stay at the level of potential: clinical signal, market fit, strategic upside.

The pressure only builds once you start mapping the actual execution.

At that point, the program is no longer judged in isolation. It’s judged against the systems it has to move through: manufacturing infrastructure, regulatory pathways, and cross-border coordination.

Most programs don’t hit one giant blocking issue.

Instead, they collect a handful of smaller, perfectly reasonable dependencies that become surprisingly hard to reconcile once they all have to work together.

Three areas consistently carry the most weight.

A process that runs smoothly in clinical batches isn’t automatically ready for commercial scale. This hits hardest with complex formulations like long-acting injectables (LAIs) or inhalation products. Without robust analytical comparability data, the tech transfer to a commercial CDMO can take months. Sometimes years of extra validation work and forced process changes that nobody budgeted for early on.

In practice, this assumption narrows the addressable market.

Healthcare systems, particularly beyond tier-one centres, are increasingly resistant to solutions that require new capital expenditure, bespoke installations, or rigid facility upgrades. Even when clinical value is well established, infrastructure-heavy approaches struggle to scale.

From a hospital and payer perspective, the total cost of adoption now includes:
• upfront capital investment
• workflow disruption
• staffing and compliance burden
• long-term operational risk

Innovation that ignores these realities faces friction, regardless of scientific merit.

Development plans almost always assume parallel progress across regions. In practice, regulatory sequencing creates dependencies that are hard to compress. What looks like a clean global launch on a slide deck often turns into a chain of staged steps where a delay in one jurisdiction quietly erodes value in another.

The path forward is no longer linear. Requirements in the major regions are moving in different directions, and alignment doesn’t happen automatically. What satisfies one authority can require real adaptation elsewhere. Especially when development, manufacturing, and documentation were originally built for a single market.

These issues aren’t new.
What has changed is how little room there is left to absorb them.

Regulatory expectations keep shifting, but not in the same direction. In the US, there’s sharper scrutiny on CMC packages and supply-chain transparency, often forcing adjustments while development is still underway. In Europe, the updated pharmaceutical framework adds extra layers of coordination and environmental considerations that many sponsors still underestimate. And with more early-stage assets now coming out of China, teams frequently have to rework clinical assumptions and documentation standards to meet Western expectations.

Taken one at a time, each of these can be managed.
Taken together, they compress flexibility.

By this stage, the asset itself hasn’t changed.
But the effort required to move it forward has.

In this environment, momentum depends less on how compelling the science is and more on how thoroughly the program has been pressure-tested before formal diligence even starts.

The deals that actually close and keep moving after signing are usually the ones that quietly answered a few basic questions early enough to avoid painful rework later.

Is the CMC package truly aligned across regions?
If the manufacturing documentation only satisfies one jurisdiction, expanding later means new stability data, validation batches, or process tweaks that eat both time and cost.

Are the clinical assumptions transferable?
Trial design, comparators, and endpoints need to hold up across every target market. Misalignment here rarely shows up in the first meetings, but it almost always surfaces when changes become expensive.

Is the manufacturing strategy genuinely scalable?
Moving from early production to a global CDMO environment demands a level of process maturity that many early-stage companies assume they have until they don’t.

These aren’t edge cases.
They’re exactly where otherwise strong programs start to slow down.

The programs that keep progressing aren’t always the most advanced or the most novel. They’re simply the ones that stay stable under pressure.

The manufacturing process holds when you scale it. The development plan actually reflects how regulatory steps are sequenced in the real world. And cross-border execution was thought about early instead of bolted on later.

There are fewer dependencies that all have to go right at the same time. Fewer assumptions that need to be revisited once the details come in.

It doesn’t remove risk.
But it keeps the path workable.

There is no shortage of strong science.
But in 2026, most decisions aren’t made on scientific quality alone.

They’re made on whether the program can move forward without introducing more complexity than the structure around it can support.

That’s the thin line where many opportunities quietly change shape and where momentum is either sustained… or slowly lost.